YOKNEAM, Israel, April 20, 2015 /CNW/ -- Syneron Medical
Ltd. (NASDAQ: ELOS), a global market leader in the
aesthetic medical device marketplace, announced today that the
PicoWay® picosecond laser received U.S. Food and Drug
Administration (FDA) clearance for the treatment of pigmented
lesions. The PicoWay picosecond laser previously received FDA
clearance for the removal of tattoos in November 2014 and was launched in the U.S. late
in the fourth quarter 2014.
PicoWay incorporates picosecond (one trillionth of a second)
pulse duration to generate an ultra-short pulse and very high peak
power of laser energy on the skin. The high energy ultra-short
picosecond laser pulse creates a strong photo-mechanical impact
that optimizes fracturing of tattoo ink or pigmentation. The
innovative PicoWay Technology™ is integrated into a proven,
reliable Candela platform which offers high reliability, superior
performance and low cost of ownership.
Amit Meridor, Chief Executive Officer of Syneron Medical, said,
"PicoWay offers our customers a reliable and easy-to-use system
featuring the shortest picosecond pulse and the highest peak power
on the market. The expansion of PicoWay's FDA clearance to include
pigmented lesions further enhances the utility of the system,
allowing practitioners to offer this next-generation technology for
more of their pigment-related procedures. It is also indicative of
our commitment to add new applications that leverage the PicoWay
technology for other treatments. Since launching the product late
last year, there has been strong interest in PicoWay and we expect
the addition of the pigmented lesion indication will further
enhance its attractiveness to customers."
The Company also announced Health Canada clearance of the
PicoWay picosecond laser for the treatment of pigmented lesions and
tattoo removal. PicoWay is a dual wavelength device, with 532nm and
1064nm wavelengths, which utilizes proprietary PicoWay Technology
to generate picosecond pulses for the treatment of pigmented
lesions and tattoos of all colors. The Health Canada clearance is
for all tattoo colors: red, yellow and orange for the 532nm
wavelength; black, brown, green, blue and purple for the 1064nm
wavelength.
The launch of PicoWay in Canada
will begin during the second quarter 2015, building on the launch
of the product in the U.S. and other international markets during
the fourth quarter 2014. The Company sells its products in
Canada through its direct North
American sales organization.
William Griffing, Chief Executive
Officer of Syneron Candela North America, said, "Based on the
strong early reception to PicoWay, we believe we are well
positioned to drive adoption in Canada based on our unique PicoWay technology,
strong Candela brand, and broad existing customer base."
About Syneron Candela
Syneron Candela is a leading global aesthetic device company
with a comprehensive product portfolio and a global distribution
footprint. The Company's technology enables physicians to
provide advanced solutions for a broad range of medical-aesthetic
applications including body contouring, hair removal, wrinkle
reduction, tattoo removal, improving the skin's appearance through
the treatment of superficial benign vascular and pigmented lesions,
and the treatment of acne, leg veins and cellulite. The Company
sells its products under three distinct brands, Syneron, Candela
and CoolTouch, and has a wide portfolio of trusted, leading
products including UltraShape, VelaShape, GentleLase, VBeam
Perfecta, PicoWay, Profound and elos Plus.
Founded in 2000, the corporate, R&D, and manufacturing
headquarters for Syneron Candela are located in Israel. Syneron Candela also has R&D and
manufacturing operations in the U.S. The company markets,
services and supports its products in 86 countries. It has
offices in North America,
France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan,
and Hong Kong and distributors
worldwide.
For additional information, please visit
http://www.syneron-candela.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
This
news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 that
involve risks and uncertainties. Such forward-looking statements
include the expectations, plans and prospects for the Company,
including product efficacy, market acceptance of new products, and
projected revenues, margins, earnings and market shares. The
statements made by the Company are based upon management's current
expectations and are subject to certain risks and uncertainties
that could cause actual results to differ materially from those
described in the forward-looking statements. These risks and
uncertainties include the risk factors and other cautionary
statements described in the Company's filings with the SEC,
including those described in the Company's most recent Annual
Report on Form 20-F, and in the filings that Syneron Medical makes
with the SEC, and other factors beyond the Company's control. If
one or more of these factors materialize, or if any underlying
assumptions prove incorrect, Syneron Medical Ltd.'s actual results,
performance or achievements may vary materially from those
expressed or implied by these forward-looking statements. These
forward-looking statements should not be relied upon as
representing Syneron Medical Ltd.'s views as of any date after the
date of this document. The Company does not intend to update these
statements and undertakes no duty to any person to provide any such
update under any circumstance.
Contacts:
Syneron Medical – Public Relations
pr@syneron.com
Hugo Goldman, Chief Financial
Officer
+ 972 73 244 2283
Email: hugo.goldman@syneron.com
Zack Kubow, The Ruth Group
646-536-7020
Email: zkubow@theruthgroup.com
Logo -
http://photos.prnewswire.com/prnh/20120528/535447
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/syneron-candelas-picoway-picosecond-laser-receives-us-fda-clearance-for-treatment-of-pigmented-lesions-300068329.html
SOURCE Syneron Medical Ltd.